Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumateperone LAI in Schizophrenia or Schizoaffective Disorder
NCT06627413Phase 1Completed
- Sponsor
- Intra-Cellular Therapies
- Start
- Aug 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lumateperone in schizophrenia and schizoaffective disorder (9 cohorts), sponsored by Intra-Cellular Therapies. Primary endpoints: Maximum Observed Plasma Concentration for Oral Administration at Day 5, Maximum Observed Plasma Concentration for Intramuscular Administration and 4 more. Started Aug 2024; status: completed.
02
Drugs
lumateperone
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT06627413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06627413.